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Abstract 19 
Therapeutic protein solutions for subcutaneous injection must be very highly concentrated, which 20 
increases their viscosity through protein-protein interactions. However, maintaining a solution 21 
viscosity below 50 cP is important for the preparation and injection of therapeutic protein 22 
solutions. In this study, we examined the effect of various amino acids on the solution viscosity 23 
of very highly concentrated bovine serum albumin (BSA) and human serum albumin (HSA) at a 24 
physiological pH. Among the amino acids tested, L-arginine hydrochloride (ArgHCl) and L-25 
lysine hydrochloride (LysHCl) (50-200 mM) successfully reduced the viscosity of both BSA and 26 
HSA solutions; guanidine hydrochloride (GdnHCl), NaCl, and other sodium salts were equally as 27 
effective, indicating the electrostatic shielding effect of these additives. Fourier transform 28 
infrared spectroscopy showed that BSA is in its native state even in the presence of ArgHCl, 29 
LysHCl, and NaCl at high protein concentrations. These results indicate that weakened protein-30 
protein interactions play a key role in reducing solution viscosity. ArgHCl and LysHCl, which 31 
are also non-toxic compounds, will be used as additives to reduce the solution viscosity of 32 
concentrated therapeutic proteins.  33 
––––––––– 34 
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Introduction 37 
 Therapeutic proteins account for an increasingly large proportion of pharmaceutical drugs 38 
in recent years. These proteins are normally administered by subcutaneous injection (1). When a 39 
high dose of therapeutic proteins is required, the protein solution must often be very highly 40 
concentrated to reduce the injection volume for patient convenience. However, such a high 41 
protein concentration frequently leads to high viscosity, posing considerable challenges for both 42 
processing and injection (2–4). For example, subcutaneous injection is generally performed with 43 
solutions under 50 cP to reduce the time required for injection (5). Therefore, maintaining a 44 
solution viscosity below 50 cP is a primary goal when developing high concentration 45 
formulations of therapeutic proteins.  46 
 The viscosity of a protein solution is caused by noncovalent protein-protein interactions 47 
such as electrostatic attraction or repulsion, leading to the formation of a transient three-48 
dimensional network of protein (6). There has been considerable effort directed toward lowering 49 
the viscosity of concentrated protein solutions through the application of various solution 50 
additives (7–11). Among them, inorganic salts (12, 13) and hydrophobic salts (5, 14) have been 51 
shown to effectively reduce the viscosity of protein solutions. However, some of these salts have 52 
adverse effects on proteins, leading to destabilization and consequent aggregate formation (15). 53 
Thus, there is always a demand for effective formulation conditions that reduce the viscosity of a 54 
solution without compromising protein stability.  55 
 We have developed the application of ArgHCl for suppressing aggregation and 56 
adsorption of various proteins during heat treatment and oxidative refolding (16–22). These 57 
effects have been ascribed, at least in part, to the interaction of aromatic groups on arginine with 58 
the protein surface (23). We have shown that ArgHCl binds to aromatic amino acids in proteins 59 
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using a crystal structure (24) and increases the solubility of low molecular weight solutes 60 
containing aromatic moieties, consistent with the above mechanism (25–29). ArgHCl does not 61 
destabilize the protein structure but decreases the probability of aggregation (30–36). Based on 62 
its effects on protein aggregation, ArgHCl might also reduce the viscosity of protein solutions by 63 
suppressing transient protein-protein interactions, thus preventing the formation of a three-64 
dimensional network. In this work, we examined the effect of various amino acids on the 65 
viscosity of bovine and human serum albumin (BSA and HSA, respectively). HSA is a clinically 66 
important supplement for the loss of body fluid. This is the first report describing the application 67 
of amino acids for reducing the viscosity of HSA solutions.  68 
 69 
 70 
Material and Methods 71 
 BSA and HSA were obtained from Sigma Chemical Co. (St. Louis, MO). The purity of 72 
BSA and HSA was more than 98% and 96%, respectively. L-Alanine (Ala), L-valine (Val), L-73 
methionine (Met), L-proline (Pro), glycine (Gly), L-serine (Ser), L-threonine (Thr), L-lysine 74 
hydrochloride (LysHCl), L-arginine hydrochloride (ArgHCl), L-histidine (His), guanidine 75 
hydrochloride (GdnHCl), sodium chloride (NaCl) were obtained from Wako Pure Chemical Inc. 76 
Ltd. (Osaka, Japan). All chemicals were of reagent grade and were used as received. 77 
 The sample solution was prepared as follows: Serum albumin was dissolved in deionized 78 
water, and the pH of the protein solution was adjusted to the desired values with 0.5 M NaOH or 79 
HCl. The additive solution was mixed with the serum albumin solution to achieve the 80 
appropriate concentrations of protein and additive, and the pH was then readjusted. 81 
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 The viscosity of the sample solution was measured with a torsional oscillation VM-10A-82 
L viscometer (CBC Materials Co. Ltd., Japan) at 25°C without depending on shear rate. A 1 ml 83 
sample was loaded onto the measuring microtube. The viscosity of each sample was measured at 84 
least in duplicate. Error bars in Figures depict the standard deviation of the mean of three 85 
independent experiments. 86 
 Fourier transform infrared (FTIR) spectra of the sample solutions were measured on a 87 
FT-IR 4200 spectrometer (JASCO Corporation, Japan) using the attenuated total reﬂection 88 
(ATR) method. The sample solution was placed on the surface of a single-reflection ZnSe prism 89 
on an ATR accessory. Spectra were collected in the range of 1,700 to 1,500 cm-1 with a spectral 90 
resolution of 2.0 cm-1. 91 
 92 
 93 
Results and Discussion 94 
Examination of the solution conditions 95 
 The viscosity of a protein solution is due, at least in part, to protein-protein interactions 96 
and is therefore expected to change with pH; this behavior is similar to protein solubility, which 97 
also depends on solution pH. The viscosity of a 40 mg/ml BSA solution as a function of pH was 98 
reported previously (37). The lowest viscosity was observed at around pH 4.8, near the isoelectric 99 
point (pI) of BSA, which is in good agreement with our experimental value (data not shown). It 100 
is clear that the viscosity is greater when BSA is positively charged at pH 4.0 and negatively 101 
charged above pH 6.0, which suggests the involvement of charge-charge repulsive interactions in 102 
network formation. Figure 1 shows that the viscosity of the BSA solution at pH 7.4 is a function 103 
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of the protein concentration up to 300 mg/ml. The solution viscosity remained nearly constant 104 
below 150 mg/ml. Further increases in protein concentration resulted in an exponential increase 105 
in viscosity to over 100 cP at 300 mg/ml.  106 
 In order to confirm the structural change by such high concentration, we measured FTIR 107 
spectra of BSA as a function of protein concentration at pH 6.8, which is the pH value of BSA 108 
solutions not adjusted, due to the avoidance of unnecessary factors (Fig. 2). The amide I and 109 
amide II regions from 1,700 to 1,500 cm-1 of the FTIR spectra were clearly observed with the 110 
BSA concentration of 75-300 mg/ml, which reflects the second structure of protein. The maximal 111 
intensity of the amide I region at 1651 cm-1 increased with increasing the protein concentration. 112 
The normalized spectra of the amide I and amide II regions of BSA with the concentration of 75-113 
300 mg/ml were identical (Fig. 2B), indicating that the secondary structure of BSA retained 114 
constant even in the presence of high protein concentration. 115 
 116 
Effect of amino acids on the viscosity of BSA solutions 117 
 Because the viscosity of BSA solution was dependent on both pH and protein 118 
concentration, we took these parameters into consideration when determining the solution 119 
conditions for evaluating the effects of various additives. We chose a pH of 7.4 because it is 120 
preferable for injectable solutions to be similar to physiological conditions. At this pH, a 275 121 
mg/ml BSA solution showed a viscosity of ~50 cP (see Fig. 1). Any additives that lower the 122 
viscosity below this value may be acceptable for pharmaceutical applications (e.g., subcutaneous 123 
injection). Using a pH of 7.4 and a concentration of 275 mg/ml, we examined the effects of 124 
additives on the viscosity of a BSA solution. 125 
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 Figure 3 shows the viscosity of a 275 mg/ml BSA solution at pH 7.4 in the presence of 126 
200 mM additives. The additives tested were the 10 naturally occurring amino acids shown in 127 
Fig. 3; other amino acids were insufficiently soluble in the presence of 275 mg/ml BSA. Other 128 
additives were also tested for control experiment; NaCl served as salts, and GdnHCl served as 129 
ArgHCl. Errors in the viscosity measurements may be mostly attributed to preparation errors 130 
such as alterations in protein concentration because no viscosity errors were noted when the same 131 
sample solution was measured. As shown in Fig. 3, the viscosity of the BSA solution was ~50 cP 132 
in the absence of additives. In the presence of 200 mM ArgHCl or LysHCl, the viscosity of the 133 
BSA solution decreased to 28 cP and 25 cP, respectively, corresponding to 1.9-fold and 2.0-fold 134 
respective reductions in viscosity relative to the solution without additives. Conversely, the other 135 
amino acids barely reduced the viscosities of the BSA solutions. The effects of NaCl and 136 
GdnHCl on viscosity were the same as those of ArgHCl and LysHCl. The observed similarity 137 
between LysHCl, ArgHCl, NaCl, and GdnHCl suggests that the ionic properties of these 138 
electrolytes may play an important role in reducing the viscosity of BSA solutions, as all of these 139 
electrolytes are monovalent ions at neutral pH.  140 
 Figure 4 shows the viscosity of 275 mg/ml BSA in the presence of 0 to 200 mM LysHCl, 141 
ArgHCl, and NaCl. The viscosity of BSA sharply decreased with increasing concentrations of 142 
ArgHCl, LysHCl, and NaCl up to ~50 mM. Above 50 mM, the viscosity of BSA appeared to 143 
reach a plateau and was nearly independent of the additives, with all additives leading to a 1.5-144 
fold reduction in viscosity. FTIR spectra showed that the secondary structure of BSA was not 145 
altered even in the presence of 200 mM ArgHCl, LysHCl, and NaCl (Fig. 5). These data indicate 146 
that BSA does not undergo structural changes during reduction of the solution viscosity.  147 
 148 
Effect of amino acids on the viscosity of HSA solutions 149 
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 Finally, we performed the same experiments with human serum albumin (HSA) which is 150 
similar in the pI and the sequence to BSA, as it has commercial value as a formulation excipient 151 
and plasma expander. Figure 6 shows the viscosity of 305 mg/ml HSA at pH 7.4 in the presence 152 
of 200 mM amino acid or salt. A pattern similar to that observed for BSA was noted; the 153 
viscosity of HSA was decreased 1.6-fold by ArgHCl and LysHCl, whereas the other amino acids 154 
had marginal effects. As with BSA, NaCl and GdnHCl were as effective as, or slightly more 155 
effective than, LysHCl and ArgHCl with respect to reducing the viscosity of the HSA solution.  156 
 157 
Molecular mechanisms of viscosity reduction by ArgHCl and LysHCl 158 
 The pH dependence of BSA solution viscosity is intriguing. The viscosity was at a 159 
minimum at approximately pH 4.8, which is near the pI of BSA (37). This result indicated that 160 
the protein-protein interactions in relation to solution viscosity were also at a minimum. In other 161 
words, the viscosity of BSA solutions significantly increased on both sides of the pI, meaning 162 
that stronger protein-protein interactions that affect solution viscosity occur when BSA acquires 163 
net charges, regardless of whether these charges are negative or positive. Although the 164 
acquisition of net charges causes overall repulsion between protein molecules, either 165 
deprotonation of carboxyl groups (below the pI) or protonation of His and Lys (above the pI) 166 
may enhance the local electrostatic interaction between BSA molecules, leading to increased 167 
formation of transient noncovalent networks and a consequent increase in solution viscosity.  168 
 We expected that protein solubility would be related to solution viscosity. Protein 169 
solubility is normally minimal at the pI (38). Near the pI, the net charge of a protein should be 170 
close to zero, causing minimal charge repulsion and enhancing protein-protein interactions. 171 
Protein-protein interactions that determine protein solubility may be related to the transient 172 
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formation of a protein network that increases solution viscosity. Thus, it was expected that the 173 
viscosity of BSA solution would be maximal near its pI. However, the viscosity was at a 174 
minimum near the pI of BSA (37). Electrostatic interactions are thought to be important in high 175 
concentration formulations of monoclonal antibodies (13, 39). Thus, this unexpected result 176 
indicated that the type of protein-protein interaction that plays a role in high viscosity is different 177 
from the type of interaction responsible for determining protein solubility.  178 
 The effects of additives were examined at the physiological pH of 7.4. At this pH, BSA 179 
has a net negative charge that apparently results in a greater viscosity than that which occurs at 180 
the isoelectric pH of ~5 (37). The current study revealed that ArgHCl or LysHCl at 200 mM 181 
significantly reduced the viscosities of both BSA and HSA solutions, although those of 50 mM 182 
may be sufficient to achieve the same level of reduction (Fig. 4). The viscosity of albumin 183 
solution was 1.6-fold lower in the presence of ArgHCl or LysHCl than in their absence. A 1.6-184 
fold reduction in viscosity (from 50 cP to 30 cP) triggered by 200 mM ArgHCl or LysHCl at a 185 
physiological pH may be sufficient for injection. To our knowledge, this is the first report on the 186 
use of amino acids to reduce the viscosity of albumin solutions under practical conditions. 187 
 The molecular mechanisms by which ArgHCl and LysHCl reduce solution viscosity will 188 
be discussed in detail below. It is evident that LysHCl and ArgHCl as well as their salts are 189 
effective for reducing the viscosity of BSA and HSA solutions. In other words, there is no 190 
specific property of Lys or Arg that plays a key role in BSA and HSA solution viscosity. We 191 
have suggested the importance of electrostatic interactions in determining the protein-protein 192 
network, which is closely related to the high viscosity of BSA and HSA solutions. It has been 193 
reported that salts can effectively weaken such electrostatic interactions (40). Thus, both LysHCl 194 
and ArgHCl may be working simply as salts. This may be the first rare case in which ArgHCl is 195 
not more effective at suppressing protein-protein interactions compared with LysHCl or salts, 196 
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which in turn suggests less involvement of aromatic or hydrophobic interactions in the viscosity 197 
of BSA and HSA solutions. When these types of interactions are involved (e.g., protein-protein 198 
interactions that determine solubility or aggregation), ArgHCl normally exerts stronger effects 199 
than any of the other additives tested here.  200 
 In conclusion, we examined the effect of amino acids on the viscosity of highly 201 
concentrated solutions of BSA and HSA. We showed that (i) ArgHCl and LysHCl are effective at 202 
reducing the viscosity of both BSA and HSA solutions, (ii) GdnHCl and NaCl equally reduce the 203 
solution viscosity of BSA, and (iii) the ionic properties of these additives play a key role in 204 
reducing the viscosity of protein solutions. These results suggested that both ArgHCl and LysHCl 205 
maybe working simply as salts, and can effectively weaken electrostatic interaction.  It should be 206 
noted that ArgHCl is one of the most used solution additive that decreases the probability of 207 
protein aggregation (30–36), adsorption on solid surface (16), and increase the solubility of 208 
water-insoluble drugs (27–29) and reduced-denatured proteins (19, 20). This is the first report 209 
that amino acids reduce the solution viscosity of HSA, which is a clinically important product 210 
that is used as a supplement for the loss of body fluid. 211 
 212 
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 328 
Figure legends 329 
Figure 1. Viscosity of BSA solutions as a function of the protein concentration at pH 7.4. 330 
Various concentrations of BSA were prepared at pH 7.4 and 25°C. 331 
 332 
Figure 2. FTIR spectra in the amide I and amide II regions of BSA solutions as a function of the 333 
protein concentration. Original (A) and normalized (B) spectra of BSA at pH 6.8 and 25°C: 75 334 
mg/ml (dotted line), 150 mg/ml (broken and dotted line), 225 mg/ml (broken line) and 300 335 
mg/ml (solid line). 336 
 337 
Figure 3. Viscosity of BSA solutions in the absence or presence of additives. Samples containing 338 
275 mg/ml BSA with 200 mM amino acid or salt were prepared at pH 7.4 and 25°C. Error bars 339 
depict the standard deviation of the mean of three independent experiments. 340 
 341 
Figure 4. Viscosity of BSA solutions as a function of additive concentration. Samples containing 342 
275 mg/ml BSA with various concentrations of LysHCl (closed circle), ArgHCl (open square) 343 
and NaCl (closed triangle) were prepared at pH 7.4 and 25°C. 344 
 345 
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Figure 5. FTIR spectra in the amide I and amide II regions of BSA solutions with additives. 346 
Samples containing 275 mg/ml BSA with 200 mM additives were prepared at pH 7.4 and 25°C: 347 
No additives (solid line), LysHCl (broken line), ArgHCl (broken and dotted line), NaCl (dotted 348 
line). 349 
 350 
Figure 6. Viscosity of HSA solutions in the absence or presence of additives. Samples 351 
containing 305 mg/ml HSA with 200 mM amino acid or salt were prepared at pH 7.4 and 25°C. 352 
Error bars depict the standard deviation of the mean of three independent experiments. 353 
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